论文部分内容阅读
目的:观察平喘汤联合舒利迭治疗哮喘的临床疗效。方法:选取山东省即墨市人民医院呼吸内科2013年1月至2014年12月收治的108例支气管哮喘患者,根据入院单双号顺序分为观察组和对照组各54例,两组患者均采用常规疗法(止咳、解痉、平喘、抗感染等)治疗,对照组采用舒利迭治疗,观察组在对照组的基础上加用平喘汤进行治疗,两组患者连续治疗14天,比较临床效果差异。结果:治疗后观察组日间及夜间喘息症状缓解时间显著短于对照组(P<0.05),血清TNF-α、IL-6、IL-8、CRP含量显著低于对照组(P<0.05),FEV1、PEFR、FVC显著高于对照组(P<0.05),日间及夜间哮喘评分显著低于对照组(P<0.05),生存质量评分及临床显效率显著高于对照组(P<0.05)。结论:平喘汤联合舒利迭治疗哮喘对于缓解临床症状、改善患者生存质量、改善实验室检查指标具有显著作用,同时有利于提高治疗显效率。
Objective: To observe the clinical efficacy of Pingchuan Decoction combined with seretide in the treatment of asthma. Methods: A total of 108 patients with bronchial asthma who were admitted to Department of Respiratory Medicine, Jimo People’s Hospital of Shandong Province from January 2013 to December 2014 were selected and divided into observation group and control group according to the sequence of admission single and double numbers respectively, 54 cases in each group were used The conventional therapy (cough, spasm, antiasthmatic, anti-infection, etc.) treatment, the control group treated with seretide, the observation group on the basis of the control group with asthma treatment, two groups of patients for 14 days of continuous treatment, Clinical differences. Results: After treatment, the remission time of wheezing in observation group was significantly shorter than that in control group (P <0.05), and the levels of TNF-α, IL-6, IL-8 and CRP in the observation group were significantly lower than those in the control group , FEV1, PEFR and FVC were significantly higher than those of the control group (P <0.05). The asthma scores at daytime and at night were significantly lower than those in the control group (P <0.05), and the quality of life score and clinical effective rate were significantly higher than those in the control group ). Conclusion: Pingchuan Decoction combined with seretide for the treatment of asthma can relieve clinical symptoms, improve the quality of life of patients, improve the laboratory test indicators, and improve the efficiency of treatment.